Publications 2021

Gullhaug A, Hjermstad MJ, Yri O, Svestad JG, Aass N, Johansen S (2021)
Use of radiotherapy in breast cancer patients with brain metastases: a retrospective 11-year single center study
J. Med. Imaging Radiat. Sci., 52 (2), 214-222
DOI 10.1016/j.jmir.2021.01.002

Karlsson AT, Hjermstad MJ, Omdahl T, Aass N, Skovlund E, Hellebust TP, Johansen S, Kaasa S, Yri OE (2021)
Overall survival after initial radiotherapy for brain metastases; a population based study of 2140 patients with non-small cell lung cancer
Acta Oncol., 60 (8), 1054-1060
DOI 10.1080/0284186X.2021.1924399

Winther RR, Vik-Mo EO, Yri OE, Aass N, Kaasa S, Skovlund E, Helseth E, Hjermstad MJ (2021)
Surgery for brain metastases - real-world prognostic factors' association with survival
Acta Oncol., 60 (9), 1161-1168
DOI 10.1080/0284186X.2021.1930150

Publications 2017

Daldorff S, Mathiesen RMR, Yri OE, Odegard HP, Geisler J (2017)
Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer
Br. J. Cancer, 116 (1), 10-20
DOI 10.1038/bjc.2016.405

Publications 2015

Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppa S, Liestol K, Smeland EB, Holte H (2015)
Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma
Leuk. Lymphoma, 56 (6), 1742-1749
DOI 10.3109/10428194.2014.970550

Riihijarvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg ML, Delabie J, Smeland E, Holte H, Leppa S (2015)
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
Haematologica, 100 (2), 238-245
DOI 10.3324/haematol.2014.113472

Publications 2013

Yri OE, Ekstrom PO, Hilden V, Gaudernack G, Liestol K, Smeland EB, Holte H (2013)
Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
Leuk. Lymphoma, 54 (10), 2205-2214
DOI 10.3109/10428194.2013.774392

Publications 2012

Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundstrom C, Christensson B, Sander B (2012)
Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
Br. J. Haematol., 156 (2), 225-233
DOI 10.1111/j.1365-2141.2011.08942.x

Yri OE, Ekstrom PO, Hilden V, Gaudernack G, Liestol K, Smeland EB, Holte H (2012)
Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma
Leuk. Lymphoma, 53 (10), 1934-1944
DOI 10.3109/10428194.2012.682307

Publications 2011

Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordoy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A (2011)
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
Blood, 118 (26), 6769-6771
DOI 10.1182/blood-2011-08-372649

Publications 2009

Yri OE, Vig J, Hegstad E, Hovde O, Pignon I, Jynge P (2009)
Mangafodipir as a cytoprotective adjunct to chemotherapy - a case report
Acta Oncol., 48 (4), PII 908152320-635
DOI 10.1080/02841860802680427